> All News
> BASL News
> Hepatology News
> Nurse News
> Trainee News
> Transplant News
News Articles 1 - 10 of 160
A new international study has found high mortality rates from COVID-19 among people with chronic liver disease and cirrhosis.
The researchers, led by teams at Oxford University Hospitals NHS Foundation Trust and the University of North Carolina, set up an international registry to collect clinical details of patients with chronic liver disease and cirrhosis who develop COVID-19.
Between 25 March 2020 and 20 April 2020, 152 cases were submitted to the registry, over 95 percent of which were hospitalised. Patients with cirrhosis had poor outcomes with an overall death rate of 40 percent. Those with advanced disease called ‘decompensated cirrhosis’ had the highest rate of death (between 43 and 63 percent), compared with 12 percent for patients with liver disease but without cirrhosis.
The paper has been published online by the Journal of Hepatology.
Dr Thomas Marjot, who leads the project alongside Dr Gwilym Webb and Professor Ellie Barnes at the Translational Gastroenterology Unit at Oxford’s John Radcliffe Hospital, said: “Until now, very little was known about the impact of COVID-19 on patients with pre-existing liver disease.
“Our data, which were gathered from 21 countries, show that people with liver disease, and especially those with decompensated cirrhosis, have particularly poor outcomes once they develop COVID-19.
“Even when other risk factors for poor outcomes - such as age, obesity, diabetes and high blood pressure - were taken into account, the severity of baseline liver disease was still associated with increased mortality,” he explained.
The study also showed that many patients with cirrhosis and COVID-19 developed features of worsening liver function (encephalopathy, ascites, bleeding), and in 24 percent of cases this occurred even without any chest symptoms or breathing difficulties.
However, Dr Marjot explained, these preliminary findings should be interpreted with caution: “our study is limited by selection bias; this is when doctors tend to report more severe cases with the worst outcomes. Many patients with cirrhosis and COVID-19 who have good outcomes will therefore not be included in the registry.”
“Nonetheless, these findings do suggest high death rates with COVID-19 in patients with cirrhosis and that contracting the virus may lead to a deterioration in liver function. Therefore, anyone coming into hospital with worsening symptoms of liver disease should be considered for coronavirus testing”.
Pamela Healy, Chief Executive of the British Liver Trust said: “This important study demonstrates the devastating impact of coronavirus on liver patients. We are asking the Government to quickly review the shielding guidance and ensure that those with the most severe forms of liver disease have clear advice and support. Whilst lockdown may be easing for many of us, these patients often have multiple complex problems and urgently need clarity and to remain protected.”
Roy Probert, Senior Communications Manager
Tel: 01865 223070
Mobile: 07747 456443
This is an exciting opportunity for a Clinical Lecturer to build upon their existing track record of clinical and academic excellence, to undertake post-doctoral research and to develop their own externally-funded research programme in Hepatology. The successful candidate will work with Dr William Alazawi within Barts Liver Centre and the Centre for Immunobiology. The group is particularly focused on non-alcoholic fatty liver disease, with recent high-impact epidemiological clinical translational and basic science publications in the field.
For further details, please visit https://www.jobs.nhs.uk/xi/vacancy/?vac_ref=915733563. Closing date for applications: 1 October 2019.
Protecting and improving the nation’s health.
New, more effective treatments are available for the hepatitis C virus (HCV), which can improve outcomes and cure the infection in most people.
To ensure as many eligible people as possible are treated, Public Health England is supporting the NHS in contacting people – and informing their GPs – if they have been diagnosed with HCV in the past but may not have cleared their infection. These patients will be offered a test to determine whether or not they have the active infection and, if so, will then be assessed for treatment.
Some people may be aware of their diagnosis and have cleared the infection spontaneously (1 in 5 people do) or have been successfully treated. However, if anyone is unsure of their HCV status and thinks they may be at risk, they should contact their GP to arrange testing.
Read the PHE and NHSE press release here > Download FINAL-4 HCV Monitoring Report Nov 18.pdf
For more information on HCV please visit: https://www.nhs.uk/conditions/hepatitis-c/
You can find the new PHE treatment report here: https://www.gov.uk/government/publications/hepatitis-c-treatment-monitoring-in-england
You can find assets for the reengagement exercise here: https://www.gov.uk/government/publications/hepatitis-c-patient-re-engagement-exercise
Two new hepatology trials have been discussed and intellectually supported by the BSG-BASL Liver Research Development Group. These are supported from the NIHR HTA funding stream.
Beta Blockers Or Placebo for Primary Prophylaxis of oesophageal varices (BOPPP) is a UK wide multi-centre liver study. It will address whether primary prophylaxis against future variceal haemorrhage with non-selective beta blockers is clinically and economically effective in patients with cirrhosis and small varices. £2.3 million will be provided to consent, treat and follow up 1,200 patients at 25 different hospitals across the UK. The trial is led by the Institute of Liver Sciences, King’s College Hospital and King’s College London Clinical Trials Unit. For more information: Download Press release BOPPP_FINAL_19.09.2018.pdf.
Antibiotic SpontanEous PeritoniTIs Cirrhosis (ASEPTIC) is a double blind placebo controlled trial to determine whether primary antibiotic prophylaxis with Cotrimoxazol substantially reduces the incidence of spontaneous bacterial peritonitis (SBP) in people with advanced liver disease. This will be the largest study of SBP prophylaxis ever, involving patients at 30 sites. The trial is led by Unveristy College London. For more information: Download ASEPTIC trial information for BSG and BASL.pdf.
Direct-acting antiviral (DAA)-based therapies are effective and well-tolerated for HCV patients with stage four to five chronic kidney disease, a meta-analysis of published studies shows.
Reviewers at the Second Hospital of Shandong University in China found 11 studies involving a total of 264 patients. The pooled SVR12 rate was 93.2% for the total population, 89.4% for sofosbuvir-based therapies, and 94.7% for non-sofosbuvir-based therapies. For HCV genotype 1 patients, the pooled SVR12 rate was 93.1%.
The pooled incidence of serious adverse events was 12.1%, and the pooled discontinuation rate because of adverse events or serious adverse events was 2.2%.
Efficacy and safety of DAA-based antiviral therapies for HCV patients with stage 4-5 chronic kidney disease: a meta-analysis. Li T, Qu Y, Guo Y et al. Liver Int. 2016 Dec 10 [Epub ahead of print]
A large observational study in the USA confirmed haemophilia per se does not have a specific influence on transplant outcomes in HCV patients, but that HIV infection increases the risk of mortality in both haemophilic (H) and non-haemophilic (NH) patients.
Researchers identified 2,502 HCV-positive liver transplant candidates from eight US university-based transplant centres between 2004 and 2010, including 144 HIV-positive and 2,358 HIV-negative; 36 H and 2,466 NH; 1,213 transplanted and 1,289 not transplanted patients.
In univariate analysis, 90-day pre-transplant mortality was associated with higher baseline MELD (hazard ratio 1.15), lower baseline platelet count (hazard ratio 1.11 per 25k/µL), and having HIV/HCV-positive haemophilia.
In multivariate analysis, pre-transplant mortality was associated with higher MELD and was significantly greater in HIV-positive than HIV- groups, but did not differ between HIV-positive H and NH (hazard ratio 1.7). Among HIV/HCV-positive, post-transplant mortality was similar between H and NH, despite lower CD4 in H.
Haemophilia liver transplantation observational study (HOTS). Ragni MV, Humar A, Stock PG et al. Liver Transpl. 2016 Dec 9 [Epub ahead of print]
A significant number of HCV patients develop a major depressive episode (MDE) during interferon-alpha (IFN-α) based immunotherapy, and several mechanisms may be involved.
Authors of a new literature review found eight unique references which met their inclusion criteria, and which involved 826 people with HCV (37.3% females). The overall MDE incidence rate was 34.8%, with follow-up ranging between four and 48 weeks. The methodological quality varied across selected studies. It was found that Interleukin-6, salivary cortisol, arachidonic acid/eicosapentaenoicacid plus ocosahexaenoic acid ratio, and genetic polymorphisms may present variations which are linked to a predisposition to INF-α-induced depression.
However, a meta-analysis could not be performed because of the diverse biological mechanisms investigated and the lack of replicated evidence. The reviewers, therefore, concluded the mechanisms involved in IFN-α-induced depression in humans remained unclear.
Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: a critical systematic review. Machado MO, Oriolo G, Bortolato B et al. J Affect Disord. 2016 Nov 27; 209:235-245 [Epub ahead of print]
Some patients with non-alcoholic steatohepatitis (NASH) show recurrence of fibrosis as early as six to 12 months following their transplant.
This emerged in a study at the Medical University of Vienna which compared the recurrence of liver fibrosis in 15 patients transplanted for NASH with 12 to cryptogenic cirrhosis (CC) patients after orthotopic liver transplantation (OLT) between 2004 and 2015.
The case load for OLT because of NASH was constantly increasing (two in 2004-2007 compared with nine in 2012-2015) whilst decreasing for CC (six in 2004-2007 compared with two in 2012-2015). Patient characteristics at OLT were similar, except for an older age and a higher BMI in the NASH patients.
Although post-OLT plasma lipid levels and the incidence of de-novo hypertension, diabetes, and hyperlipidemia were similar between groups, the post-transplant NAFLD fibrosis score (NFS) re-increased in the NASH group but not in the CC group (-0.1317 versus -1.3645 at 12 months post-OLT.
The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. Unger LW, Herac M, Staufer K et al. Eur J Gastroenterol Hepatol. 2016 Dec 2 [Epub ahead of print]
A new study has concluded that the new direct-acting antivirals (DAAs) are highly effective with minimal adverse effects for the treatment of HCV in haemodialysis, and are a very important advance in HCV management.
In this retrospective study, HCV antibodies were analysed in 465 patients at two Madrid hospitals. Positive antibodies were found in 54, and, among these, 29 with genotypes 1 and 4 were treated with different DAA regimens, including combinations of paritaprevir/ritonavir, ombitasvir, dasabuvir, sofosbuvir, simeprevir, daclatasvir and ledipasvir, with/without ribavirin. The most important aetiology of chronic kidney disease involved glomerular abnormalities.
In all cases, a sustained viral response was achieved after 24 weeks, regardless of DAA regimen received. Adverse effects were not relevant and no case required stopping treatment. In 15 cases, ribavirin was combined with the DAA. In these cases, the most significant adverse effect was an anaemic tendency, which was reflected in the increase of the dose of erythropoietin stimulating agents, although none required transfusions.
Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients. Abad S, Vega A, Rincón D et al. Nefrologia. 2016 Nov 30 [Epub ahead of print]
Although tenofovir (TDF) was more effective at three months, there was no significant difference between TDF and entecavir (ETV) in the long-term treatment of HBV related liver cirrhosis, a new meta-analysis of studies found.
A literature search, conducted by reviewers from Beijing You'an Hospital, found significant difference of ALT norm level at three months (RR 1.43) and six months (RR 0.89), and significant difference of undetectable HBV-DNA only at three months follow-up period (RR 1.59) between TDF and ETV, but no significant difference in the long-term period. There was a significant difference between TDF and ETV in eGFR level (RR 1.601) and hypophosphatemia incidence (RR 4.008).
The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and meta-analysis. Han Y, Zeng A, Liao H et al. Int Immunopharmacol. 2016 Dec 1;42: 168-175 [Epub ahead of print]